Survival Outcomes of Gynecologic Oncology Patients at Assiut University
ConditionGynaecological Oncology
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
AgeNot listed
SponsorAssiut University
About this trial
This retrospective cohort study investigates survival outcomes of gynecological oncology patients treated at Assiut University Hospital between 2022 and 2025, comparing them to international benchmarks and assessing factors affecting survival.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
All female patients diagnosed with gynecological cancers (including ovarian, cervical, endometrial, vulvar, and vaginal cancer) and treated at Assiut University Gynecological Oncology Department between January 1, 2022, and December 31, 2025, will be included. Patients of all ages and backgrounds are eligible. Exclusion criteria are non-gynecological cancers, metastatic cancers originating outside the gynecologic tract, incomplete medical records, or significant comorbidities that independently affect survival (e.g., advanced heart failure, severe liver or renal disease, or unrelated terminal illnesses).
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Overall Survival
Overall survival (OS) is defined as the duration of time from the date of cancer diagnosis or initiation of treatment until death from any cause. Patients will be censored at the date of last follow-up if alive at study end. This outcome will provide a direct estimate of survival rates among gynecological oncology patients treated at Assiut University Hospital.
Time frame
4 yearsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: